Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Share-based Compensation (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Share-based Compensation for 7 consecutive years, with $43.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 206.78% year-over-year to $43.4 million, compared with a TTM value of $97.8 million through Dec 2025, up 90.48%, and an annual FY2025 reading of $97.8 million, up 90.48% over the prior year.
  • Share-based Compensation was $43.4 million for Q4 2025 at Avidity Biosciences, up from $19.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $43.4 million in Q4 2025 and bottomed at $3.7 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $11.6 million, with a median of $9.6 million recorded in 2023.
  • The sharpest move saw Share-based Compensation surged 724.28% in 2021, then increased 13.2% in 2024.
  • Year by year, Share-based Compensation stood at $4.5 million in 2021, then skyrocketed by 61.8% to $7.3 million in 2022, then surged by 34.73% to $9.8 million in 2023, then surged by 43.76% to $14.2 million in 2024, then surged by 206.78% to $43.4 million in 2025.
  • Business Quant data shows Share-based Compensation for RNA at $43.4 million in Q4 2025, $19.0 million in Q3 2025, and $17.7 million in Q2 2025.